Answers are grounded in this paper and cite their sources.
Insulin resistance (IR) contributes to type 2 diabetes (T2DM), metabolic dysfunction-associated steatotic liver disease and cardiovascular disease. Human genetics and preclinical studies link the hepatokine activin E, encoded by INHBE, and its type I receptor ALK7 to body-fat distribution, adipose lipolysis and metabolic control. Large exome-sequencing studies associate heterozygous INHBE predicted loss-of-function (pLOF) variants with lower body mass index-adjusted waist-to-hip ratio; one multi-ancestry study also reported more favorable metabolic traits and approximately 28% lower odds of T2DM. ACVR1C coding variants show similar associations, although ALK7 receives input from several ligands. Hepatocytes upregulate INHBE during non-esterified fatty-acid load and cellular stress. In mouse and adipocyte systems, secreted activin E signals through adipocyte ALK7 complexes containing ActRIIA or ActRIIB, activates SMAD2/3, and suppresses PPARγ-dependent lipolytic programs and β3-adrenergic signaling. This feedback preserves lipid stores during fasting but may promote adipocyte hypertrophy and catecholamine resistance in obesity. Lower activin E-ALK7 signaling is associated with more favorable fat distribution in human genetics, whereas reduced fat mass in mouse loss-of-function models can coexist with hepatic lipid accumulation and impaired insulin action. In one constitutive high-fat-fed mouse model, complete Inhbe loss increased hepatic lipid burden and produced a lean MASH-like phenotype. Durable efficacy and long-term hepatic safety require clinical validation. This review examines activin E biology, human genetics and preclinical evidence at three intervention levels: the activin E ligand, the ALK7 receptor and shared type II receptors, with particular attention to hepatic safety.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: